Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Oscar Lambret
• Treatments: Cisplatin; Fluorouracil

Criteria

Inclusion Criteria:

• Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a), histologically proven

• Treated by exclusive concomitant radiochemotherapy

• Written informed consent

Exclusion Criteria:

• Presence of a second uncontrolled cancer

• Metastatic carcinoma

• Metastatic disease, except cervical lymphnodes... (M1a)

• In situ carcinoma

• Eso-gastric junction cancer (Siewert II ou III)

• Inclusion in a clinical trial with an experimental drug during the study and until 15 weeks after the end of radiotherapy)